ライフサイエンスコーパス: serum iron level

1 els of serum cholesterols and persistent low serum iron level.

2 lted in reduced liver hepcidin and increased serum iron levels.

3 hepcidin production and increased tissue and serum iron levels.

4 2 in Hfe-null mice had no effect on liver or serum iron levels.

5 evels induced by BMP2/9, resulting in normal serum iron levels.

6 tissue ferroportin expression and determines serum iron levels.

7 erroportin downregulation and a reduction of serum iron levels.

8 e induces hepcidin and diminishes tissue and serum iron levels.

9 tion [SD] increase in genetically determined serum iron levels 0.72, 95% confidence interval [CI] 0.6

10 gue-Dawley rats resulted in no change in the serum iron level, a marked increase in the urinary excre

11 ions and inflammation, causing a decrease in serum iron levels and contributing to the development of

12 ive iron overload in the liver and increased serum iron levels and iron deposition in several organs

13 le T cells resulted in a significant rise in serum iron levels and liver iron content.

14 itionally, the Btbd9 mutant mice had altered serum iron levels and monoamine neurotransmitter systems

15 rpuscular volume, mean corpuscular Hb level, serum iron level, and Tfsat, and increased red blood cel

16 and 1200 ng/ml (reference 100 to 199 ng/ml), serum iron levels between 60 and 120 microg/ml (referenc

17 hich is secreted by the liver, and decreases serum iron levels by causing the down-regulation of the

18 decreased hepcidin expression and increased serum iron levels by mobilizing iron from splenic stores

19 Hepcidin reduces serum iron levels by promoting degradation of the iron e

20 eral or oral administration to mice, lowered serum iron levels comparably to those after parenteral n

21 The results suggest that elevated serum iron levels coupled with either high VLDL-C or low

22 ide association study summary statistics for serum iron levels from two cohorts and two previous meta

23 nistic support for interventions that reduce serum iron levels in individuals at risk for hypertrigly

24 els of bioactive hepcidin and its effects on serum iron levels in mice infected with Borrelia burgdor

25 dietary iron caused significant elevation of serum iron levels in p53(-/-) mice.

26 Increasing serum iron levels in patients may thus improve prognosis

27 serum phosphate concentrations and increased serum iron levels in the Col4alpha3 knockout mice.

28 mobilizes splenic iron stores, and increases serum iron levels in vivo.

29 increases hepcidin expression and decreases serum iron levels in vivo.

30 Deferoxamine infusion decreased serum iron levels (P<0.001).

31 Iron loading was confirmed by increases in serum iron levels, percentages of transferrin saturation

32 independently associated with elevations in serum iron level, serum transferrin-iron saturation, ser

33 lso associated with significant increases in serum iron levels, total iron-binding capacity, and tran

34 was associated with significant increases in serum iron levels, total iron-binding capacity, and tran

35 In conclusion, higher serum iron level was associated with lower risk of NAFLD

36 Serum iron levels were decreased with DFO treatment afte

37 However, serum iron levels were reduced to a significantly greate

38 LFKO(-/-) mice on either diet, although the serum iron levels were slightly elevated in LFKO-/- mice

39 ped an anemia associated with abnormally low serum iron levels, yet accumulated hepatic and renal iro